188 related articles for article (PubMed ID: 35082669)
21. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.
Okabe S; Tauchi T; Tanaka Y; Kitahara T; Kimura S; Maekawa T; Ohyashiki K
Cancer Biol Ther; 2014 Feb; 15(2):207-15. PubMed ID: 24100660
[TBL] [Abstract][Full Text] [Related]
22. Effects of NVP-BEZ235, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, on HTLV-1-infected T-cell lines.
Ishikawa C; Senba M; Mori N
Oncol Lett; 2018 Apr; 15(4):5311-5317. PubMed ID: 29552172
[TBL] [Abstract][Full Text] [Related]
23. The dual PI3K/mTOR inhibitor NVP-BEZ235 inhibits proliferation and induces apoptosis of burkitt lymphoma cells.
Li C; Xin P; Xiao H; Zheng Y; Huang Y; Zhu X
Cancer Cell Int; 2015; 15():65. PubMed ID: 26130968
[TBL] [Abstract][Full Text] [Related]
24. Activation of the PI3K/mTOR pathway is involved in cystic proliferation of cholangiocytes of the PCK rat.
Ren XS; Sato Y; Harada K; Sasaki M; Furubo S; Song JY; Nakanuma Y
PLoS One; 2014; 9(1):e87660. PubMed ID: 24498161
[TBL] [Abstract][Full Text] [Related]
25. Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy.
Chang Z; Shi G; Jin J; Guo H; Guo X; Luo F; Song Y; Jia X
Int J Mol Med; 2013 Jun; 31(6):1449-56. PubMed ID: 23588698
[TBL] [Abstract][Full Text] [Related]
26. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.
Chiarini F; Grimaldi C; Ricci F; Tazzari PL; Evangelisti C; Ognibene A; Battistelli M; Falcieri E; Melchionda F; Pession A; Pagliaro P; McCubrey JA; Martelli AM
Cancer Res; 2010 Oct; 70(20):8097-107. PubMed ID: 20876803
[TBL] [Abstract][Full Text] [Related]
27. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
[TBL] [Abstract][Full Text] [Related]
28. NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity.
Fokas E; Yoshimura M; Prevo R; Higgins G; Hackl W; Maira SM; Bernhard EJ; McKenna WG; Muschel RJ
Radiat Oncol; 2012 Mar; 7():48. PubMed ID: 22452803
[TBL] [Abstract][Full Text] [Related]
29. Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.
Kuger S; Flentje M; Djuzenova CS
Radiat Oncol; 2015 Oct; 10():214. PubMed ID: 26498922
[TBL] [Abstract][Full Text] [Related]
30. Autophagy inhibition enhances colorectal cancer apoptosis induced by dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
Yang X; Niu B; Wang L; Chen M; Kang X; Wang L; Ji Y; Zhong J
Oncol Lett; 2016 Jul; 12(1):102-106. PubMed ID: 27347108
[TBL] [Abstract][Full Text] [Related]
31. Dual blocking of PI3K and mTOR signaling by NVP-BEZ235 inhibits proliferation in cervical carcinoma cells and enhances therapeutic response.
Xie G; Wang Z; Chen Y; Zhang S; Feng L; Meng F; Yu Z
Cancer Lett; 2017 Mar; 388():12-20. PubMed ID: 27894954
[TBL] [Abstract][Full Text] [Related]
32. CHKB-AS1 enhances proliferation and resistance to NVP-BEZ235 of renal cancer cells via regulating the phosphorylation of MAP4 and PI3K/AKT/mTOR signaling.
Chen X; Zhang T; Ren X; Wei Y; Zhang X; Zang X; Ju X; Qin C; Xu D
Eur J Med Res; 2023 Dec; 28(1):588. PubMed ID: 38093375
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells.
Leung E; Kim JE; Rewcastle GW; Finlay GJ; Baguley BC
Cancer Biol Ther; 2011 Jun; 11(11):938-46. PubMed ID: 21464613
[TBL] [Abstract][Full Text] [Related]
34. NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells.
Moon du G; Lee SE; Oh MM; Lee SC; Jeong SJ; Hong SK; Yoon CY; Byun SS; Park HS; Cheon J
Int J Oncol; 2014 Sep; 45(3):1027-35. PubMed ID: 24969552
[TBL] [Abstract][Full Text] [Related]
35. NVP-BEZ235, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, prominently enhances radiosensitivity of prostate cancer cell line PC-3.
Zhu W; Fu W; Hu L
Cancer Biother Radiopharm; 2013 Nov; 28(9):665-73. PubMed ID: 23768063
[TBL] [Abstract][Full Text] [Related]
36. The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer.
Roper J; Richardson MP; Wang WV; Richard LG; Chen W; Coffee EM; Sinnamon MJ; Lee L; Chen PC; Bronson RT; Martin ES; Hung KE
PLoS One; 2011; 6(9):e25132. PubMed ID: 21966435
[TBL] [Abstract][Full Text] [Related]
37. NVP-BEZ235 Attenuated Cell Proliferation and Migration in the Squamous Cell Carcinoma of Oral Cavities and p70S6K Inhibition Mimics its Effect.
Hsu CM; Lin PM; Lin HC; Tsai YT; Tsai MS; Li SH; Wu CY; Yang YH; Lin SF; Yang MY
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30423811
[TBL] [Abstract][Full Text] [Related]
38. Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines.
Masuda M; Shimomura M; Kobayashi K; Kojima S; Nakatsura T
Oncol Rep; 2011 Nov; 26(5):1273-9. PubMed ID: 21725613
[TBL] [Abstract][Full Text] [Related]
39. The combination of NVP-BEZ235 and rapamycin regulates nasopharyngeal carcinoma cell viability and apoptosis via the PI3K/AKT/mTOR pathway.
Luo H; Yu YY; Chen HM; Wu W; Li Y; Lin H
Exp Ther Med; 2019 Jan; 17(1):99-106. PubMed ID: 30651769
[TBL] [Abstract][Full Text] [Related]
40. Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer.
Elfiky AA; Aziz SA; Conrad PJ; Siddiqui S; Hackl W; Maira M; Robert CL; Kluger HM
J Transl Med; 2011 Aug; 9():133. PubMed ID: 21834980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]